Skip to main content

Table 3 Objective response in our study population

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

 

Patient n = 148

Best response, (%)

 CR

0.6

 PR

16

 SD

54

 PD

29.4

 DCR (CR + PR + SD)

70.6

 ORR (CR + PR)

16.6

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us